European Commission logo
English English
CORDIS - EU research results

Unravelling the role of scleral events on a novel treatment for Myopia using microscopy techniques

Project description

Novel insight into myopia

Myopia or near-sightedness has recently seen an alarming increase among young people, reaching 30 % in Europe and the USA and over 80 % in Asia. Since refractive surgery constitutes the only therapy for myopia, there is a pressing need to better understand the underlying causes of the condition and develop new treatments. To this end, the EU-funded MYOMICRO project will develop innovative optical instruments that enable myopic eye characterisation in unprecedented detail. Scientists will investigate the optical, structural and mechanical properties of myopic eyes, advancing our knowledge on the biological alterations that take place during myopia development. The project's results are expected to advance existing treatment solutions.


Myopia prevalence has increased dramatically in the last few decades. It has reached 30% among young population in Europe and U.S.A. and over 80% in Asia. However, refractive correction remains the only option for treatment. Myopia has been linked to the shifting balance between far- and near-vision activities and the resulting abnormal axial growth of the eye,
but many key questions remain unanswered, which are critical for exploring new treatments.

The goal of my research is to advance our understanding of myopic eyes and help to develop new treatments for myopia. As an important step, I propose to develop new innovative optical instruments with which we can characterize myopic eyes in unprecedented details to gain novel insights, and also to assess treatment effects objectively and comprehensively beyond conventional vision tests.

Specifically, I aim to accomplish the following: (a) substantial advances in the understanding of physical changes underlying myopia, (b) quantitative assessment of optical, structural, and mechanical properties of the eye during myopia development, and (c) anatomical- and structural-level assessment of novel interventions to stop myopia progression.

The applicant will lead this proposed project, termed MYOMICRO, as a collaborative project between the EU beneficiary (VioBio Lab, CSIC, Spain), and the partner organization (Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, USA). A short research stay (Visual Sciences group, University of Newcastle,
Australia) in a secondary partner organization is included. The outcome of this project will enhance the EU leading position in vision care.


Net EU contribution
€ 263 732,16
28006 Madrid

See on map

Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Total cost
€ 263 732,16

Partners (1)